CMPX Simply Wall St. 3 days ago Compass Therapeutics (CMPX) Is Up 17.2% After Analyst Highlights Pipeline Progress and Anticipated Tovecimig Data – Has the Bull Case Changed?
CMPX Insider Monkey 3 days ago Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement
CMPX Simply Wall St. 3 days ago A Look at Compass Therapeutics (CMPX) Valuation Following Strong CTX-10726 Preclinical Data and Management Update
